Skip to main content
About Kibow Therapeutics

Dedicated to Helping Patients with Chronic Kidney Disease

We are advancing potential first-in-class live biotherapeutics for CKD and ESRD.

Kibow Therapeutics is a clinical-stage developer of live biotherapeutics for persons with chronic kidney disease (CKD). The Company is advancing potential first-in-class therapies to selectively modulate the gut microbiome to improve kidney function and quality of life. Kibow Therapeutics is focused first on KT-301, an encapsulated consortium of proprietary strains of commensal bacteria targeting uremic toxins associated with CKD. Phase 2 clinical studies in CKD patients are underway to assess KT-301’s safety and its ability to halt or slow progression of CKD. A Phase 2 study in end-stage renal disease (ESRD) patients undergoing dialysis is also planned. Kibow Therapeutics is a wholly-owned subsidiary of Kibow Biotech, a developer of scientifically formulated probiotic/prebiotic dietary supplements for kidney health and general wellness purposes. Kibow Therapeutics is headquartered in Newtown Square, PA.

Kibow Means Hope

Our Heritage

Kibow Therapeutics is a wholly-owned subsidiary of Kibow Biotech, a Newtown Square, PA-based developer of non-drug dietary supplements.

Now in its 25th year, Kibow Biotech is a leading source of scientifically formulated probiotic/prebiotic dietary supplements. Guided by its visionary founder, Natarajan Ranganathan, Ph.D., and a group of internationally recognized scientific advisors, Kibow Biotech has accomplished pharmaceutical-like development and validation for its proprietary probiotic/prebiotic formulations for kidney health and general wellness purposes. Kibow Biotech has been awarded highly competitive Small Business Innovation Research (SBIR) Grant Awards from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK-NIH) and Qualifying Therapeutic Discovery Project (QTDP) Programs. Additionally, Kibow Biotech has secured USAID grant funding for R&D and product development.

Kibow Biotech is a leader provider of probiotic dietary supplements for kidney health, marketed under the brand names Renadyl™ and Azodyl® (for veterinary use).

Leadership

Our leadership team includes creative, resourceful, and well-connected life sciences industry veterans. In addition, we bring 25 years of operating experience as a developer of live biotherapeutics across multiple domains, with a focus on kidney health.

Graham Lumsden

Chief Executive Officer and Director

Robert Segal, M.D.

Medical / Scientific Advisor

Emmanuel Anteyi, M.D.

Medical Director

Mukesh Kumar, Ph.D.

Regulatory Affairs, QA, Clinical Operations

Natarajan Ranganathan, Ph.D.

Board Chair, Founder

We Strive to Improve Outcomes with Our Novel Adjunctive CKD Therapies

Chronic kidney disease (CKD) is characterized by a gradual loss of kidney function. As many as one in nine U.S. adults has CKD. Kibow Therapeutics is advancing novel, non-invasive therapies to improve quality of life and slow the progression of CKD.

Graham Lumsden, BVM&S, DipM, MRCVS

Chief Executive Officer, Director

Dr. Lumsden is the Chief Executive Officer of Kibow Therapeutics. Prior to joining Kibow, he was President and CEO of Biomarck Pharmaceuticals, a clinical stage biotechnology company focused on treating patients with inflammatory and immunological diseases. Prior to Biomarck, Dr. Lumsden was CEO of Motif Bio, where he raised $125 million and led two IPOs (AIM and NASDAQ) to advance iclaprim, a targeted antibacterial, through Phase 3 and NDA submission. Dr. Lumsden previously founded and was the CEO of Tiemed LLC, a biotech company developing solutions for patients with difficulties taking oral medicines. Dr. Lumsden spent more than twenty years at Merck & Co., where he gained global experience in both the veterinary and human health markets. Dr. Lumsden received his Bachelor of Veterinary Medicine & Surgery from University of Edinburgh and his Postgraduate Diploma in Marketing from the Chartered Institute of Marketing in the U.K.

LinkedIn

Robert Segal, M.D., F.A.C.P.

Medical / Scientific Advisor

Dr. Segal has over 30 years of life sciences industry experience including in the design, conduct, and execution of numerous multi-national, multi-site clinical programs and non-clinical studies. Dr. Segal previously served as Chief Medical Officer at Discovery Laboratories (now Windtree Therapeutics), where, in addition to serving as executive management, he focused on many successful Federal funding opportunities, including important biodefense initiatives. Dr. Segal has received well in excess of $10 million in NIH awards to evaluate novel drug and drug-device combination therapies. Previously, at Merck he held the position of Director, Cardiovascular Clinical Research where he was a key contributor to the approval and launch of Cozaar® (losartan). Prior to joining Merck, he was an Assistant Professor of Medicine in the Division of Nephrology / Transplantation at University of California, Los Angeles School of Medicine and served as an advisor to the Biotechnology Program at Northwestern University. Dr. Segal received his medical degree from the University of Pretoria Medical School, South Africa.

LinkedIn

Emmanuel Anteyi, M.D., F.C.R.P., M.B.A.

Medical Director

Dr. Anteyi plays a key role in the planning, monitoring, coordinating, and project management of clinical studies. Dr. Anteyi has been an Internal Medicine Physician and Nephrologist for over 29 years with vast experience in clinical research and clinical practice. Dr. Anteyi has served as an Adjunct Professor, Institutional Chair, and Director of Graduate Medical Education for the West African College of Physicians and the Royal College of Physicians of London (UK). Dr. Anteyi earned his Medical Degree in Nigeria and was board-certified in Internal Medicine and Nephrology by the West African College of Physicians. He was subsequently awarded the prestigious Fellowship of Royal College of Physicians of London in the United Kingdom. Dr. Anteyi later obtained a Master of Business Administration (MBA) in International Healthcare Management from Frankfurt School of Finance and Management, Frankfurt, Germany.

LinkedIn

Mukesh Kumar, Ph.D.

Regulatory Affairs, QA, Clinical Operations

Dr. Kumar is a Washington DC-based consultant in regulatory affairs and quality assurance for manufacturers and developers of pharma and biotech products. He has been involved in more than 100 multi-national clinical trials, has made hundreds of submissions to the U.S. FDA, EMA, and regulators in more than 40 countries. Dr. Kumar has created and led numerous teams for development of pharmaceutical, biotech and medical device products all the way from early-stage development to commercial markets. Dr. Kumar is a visiting professor at George Washington University, Washington DC, and Montgomery College, Maryland. He received a Ph.D. in Biochemistry from Delhi University.

LinkedIn

Natarajan Ranganathan, Ph.D.

Board Chair, Founder

Dr. Ranganathan (Dr. Rangan) is the Board Chair and Founder of Kibow Biotech. For more than twenty years,  Dr. Ranganathan has provided scientific leadership to optimally deploy probiotics and prebiotics across a variety of use cases. Under his guidance, Kibow Biotech has flourished as a scientifically-backed provider of high quality over the counter products. Dr. Ranganathan obtained his Ph.D. in bio-organic chemistry from Temple University. He received further academic training at the University of Pennsylvania and at and Johns Hopkins University.

LinkedIn

Mahesh Ranganathan

Director

Mr. Ranganathan came to Kibow in 2008, after nearly a decade serving as a global project consultant for American Express and KPMG. Mr. Ranganathan brings his significant expertise in international market development, client relations, global regulatory claims, and product registry to Kibow. Mr. Ranganathan received a BS in Marketing from Philadelphia University and an MBA in International Marketing from Saint Joseph’s University. He is proficient in Spanish, French, and Japanese with a working knowledge of Portuguese and Italian.

Chris Yochim

Director

Mr. Yochim is a leader in the Greater Philadelphia Life Science Community, promoting industry and academic collaborations, to drive innovative science towards commercialization for the benefit of patients. In 2015, Mr. Yochim retired after an expansive 35 years with ICI/ AstraZeneca, where he flourished in many leadership positions. In January 2017, Mr. Yochim was appointed Head of Business Development for the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) based at The Biotech Institute at University of Delaware. He is a Founding Member and Chairman of the Board of the Delaware Bioscience Association.

LinkedIn

Greg Bosch, M.B.A.

Director

Mr. Bosch brings over 30 years in healthcare to Panavance, a company focused on improving the effectiveness of cancer treatments, with leadership of commercial, operations, and R&D teams in the U.S. and Europe. His general management experience in the life science industry spans the pharmaceutical, biologics and medical device segments including building a biosurgery business to $220M in five years, acquiring public and private companies, and taking a company public. Prior to joining Panavance, Greg was Chief Executive Officer of Geistlich Pharma North America, where he led a cross functional team to achieve the market leadership position in regenerative medicine in the U.S. dental field. Greg earned his B.A. in Public Policy from Duke University and MBA from DePaul University.

LinkedIn

Steve Kirton

Director

Mr. Kirton is the founder and CEO of Circa Healthcare, a strategic healthcare communications agency. During his 11-year tenure with an international medical diagnostics company based in the UK, Mr. Kirton rose from Sales Representative to Director of International Sales and Marketing. He then moved to the U.S. and held a role as Business Unit Manager for Centocor, a leading biopharmaceutical company. His corporate experience was followed by several years as an ad agency executive, not only at his own company, but also at New York-based Euro RSCG Life.

LinkedIn